The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Durable complete response and overall survival in patients with heavily pretreated, poor-prognosis non-Hodgkin lymphoma to immunoactivating AVM0703 with few and mild drug-related adverse effects.
 
Lihua Elizabeth Budde
Consulting or Advisory Role - ADC Therapeutics; AstraZeneca; BeiGene; Bristol-Myers Squibb/Celgene; Kite/Gilead; Loxo/Lilly; Novartis; nurix; Roche/Genentech
Research Funding - Amgen; AstraZeneca; Merck; MustangBio
Patents, Royalties, Other Intellectual Property - CCR4 CAR T cells for treatment of patients with CCR4 positive cancer.; CD33CAR for treatment of patients with CD33+ acute myeloid leukemia.
Travel, Accommodations, Expenses - AstraZeneca; Kite/Gilead; Roche/Genentech
 
Theresa Deisher
Employment - AVM Biotechnology
Leadership - AVM Biotechnology
Stock and Other Ownership Interests - AVM Biotechnology
Research Funding - AVM Biotechnology
Patents, Royalties, Other Intellectual Property - AVM Biotechnology
Travel, Accommodations, Expenses - AVM Biotechnology
 
Don A. Stevens
No Relationships to Disclose
 
Gary J. Schiller
Stock and Other Ownership Interests - Amgen; Bristol-Myers Squibb; Johnson & Johnson
Consulting or Advisory Role - Abbvie; Agios; Astellas Pharma; Autolus Therapeutics; Bristol-Myers Squibb/Celgene; Celgene; Incyte; Jazz Pharmaceuticals; Novartis; Ono Pharmaceutical; Rigel
Speakers' Bureau - Abbvie; Agios; Amgen; Astellas Pharma; Blueprint Medicines; Bristol-Myers Squibb; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Rigel; Sanofi; Seattle Genetics/Astellas; Stemline Therapeutics
Research Funding - Abbvie; Actinium Pharmaceuticals; Actuate Therapeutics; Agios; Amgen; Aptevo Therapeutics; Arog; Astellas Pharma; AVM Biotechnology; Bio-Path Holdings; Biomea Fusion; Biosight; Bristol-Myers Squibb/Celgene; Celator; Cellectis; Celularity; Cogent Biosciences; Constellation Pharmaceuticals; Cullinan Oncology; Daiichi Sankyo; Deciphera; Delta-Fly Pharma; ElevateBio; Fate therapuetics; FORMA Therapeutics; Fujifilm; Gamida Cell; Genentech/Roche; Geron; glycomimetics; Immune-Onc Therapeutics; Incyte; Jazz Pharmaceuticals; Karyopharm Therapeutics; Kite, a Gilead company; Kronos Bio; Kura Oncology; Loxo; Marker Therapeutics; Mateon Therapeutics; Novartis; Onconova Therapeutics; Ono Pharmaceutical; Pfizer; PrECOG; REGiMMUNE; REGiMMUNE; Samus Therapeutics; Sangamo Bioscience; Sanofi; Sellas Life Sciences; Stemline Therapeutics; Syros Pharmaceuticals; Syros Pharmaceuticals; Takeda; Tolero Pharmaceuticals; Trovagene
 
Stefano R. Tarantolo
No Relationships to Disclose
 
Ryan C. Ramaekers
No Relationships to Disclose
 
Peter Jarzyna
Employment - AVM Biotechnology
Leadership - AVM Biotechnology
Stock and Other Ownership Interests - AVM Biotechnology
Research Funding - AVM Biotechnology
Patents, Royalties, Other Intellectual Property - AVM Biotechnology
 
Spencer Sawas
Employment - AVM Biotechnology Inc.
Stock and Other Ownership Interests - AVM Biotechnology Inc.
Research Funding - AVM Biotechnology Inc
Travel, Accommodations, Expenses - AVM Biotechnology Inc.
 
Sandeep Mittal
Employment - AVM Biotechnology
Stock and Other Ownership Interests - AVM Biotechnology
Research Funding - AVM Biotechnology
Travel, Accommodations, Expenses - AVM Biotechnology